Atrial fibrillation: Current knowledge and recommendations for management

European Heart Journal

Volumn 19, Issue 9, 1998, Pages 1294-1320

  Levy S ^a   Breithardt, G ^b   Campbell, R W F ^b   Camm, A J ^b   Daubert, J C ^b   Allessie, M ^b   Aliot, E ^b   Capucci, A ^b   Cosio, F ^b   Crijns, H ^b   Jordaens, L ^b   Hauer, R N W ^b   Lombardi, F ^b   Luderitz B ^b  

^a HÔPITAL NORD   (France)

^b NONE

Author keywords

Antiarrhythmic agents; Anticoagulant therapy; Atrial fibrillation; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CIBENZOLINE; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; HEPARIN; IBUTILIDE FUMARATE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

ARTIFICIAL HEART PACEMAKER; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR DISEASE; DEFIBRILLATOR; ELECTROCARDIOGRAPHY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; NOMENCLATURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QRS COMPLEX; REVIEW; RR INTERVAL; SINUS RHYTHM; T WAVE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CONTROLLED CLINICAL TRIALS; ELECTRIC COUNTERSHOCK; EMBOLISM; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PREVALENCE; PROGNOSIS; RECURRENCE; TERMINOLOGY; TREATMENT OUTCOME;

EID: 0032169177     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1050     Document Type: Review

References (213)

1. [1] Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990; 61: 714-7.
2. [2] Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986; 17: 622-6.
3. [3] Zipes D. Cardiac arrhythmias. In: Braunwald W. Heart Disease. Philadelphia: W.B. Saunders 1984: 669-70.
4. [4] Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation; the Framingham study. N Engl J Med 1982; 306: 1018-22.
5. [5] Bellet S. Clinical disorders of the heart beat. Philadelphia: Lea and Febiger 1971: 223-33.
6. [6] Page RL, Wilkinson WE, Clair WK et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
7. [7] Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissmer MD. Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation (Abstr). J Am Coll Cardiol 1992; 19: 41 A.
8. [8] Zipes DP. Atrial fibrillation. A tachycardia-induced atrial cardiomyopathy. Circulation 1997; 95: 562-4.
9. [9] Lévy S, Novella P, Ricard Ph, Paganelli F. Paroxysmal atrial fibrillation: A need for classification. J Cardiovasc Electrophysiol 1995; 6: 69-74.
10. [10] Sopher SM, Camm AJ. Therapy for atrial fibrillation: control of the ventricular response and prevention of recurrence. Cor Art Dis 1995; 6: 106-14.
11. [11] Brand FN, Abott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-years follow up in the Framingham Study. JAMA 1985; 254: 3449-53.
12. [12] Wolf PA, Abbott RD, Kannel WB. A major contributor to stroke in the elderly. Arch Int Med 1987; 147: 1561-4.
13. [13] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke; The Framingham Study. Stroke 1991; 22: 983-8.
14. [14] Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM for the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
15. [15] Manolio TA, Furberg CD, Rautaharju PM et al. Cardiac arrhythmias on 24 hours ambulatory electrocardiography in older women and men. The Cardiovascular Health Study. J Am Coll Cardiol 1984; 23: 916-25.
16. [16] Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-74.
17. [17] Lévy S, Attuel P. Fauchier JP, Medvedowsky JL et le Groupe de Travail en Rythmologie de la Société Française de cardiologie. Nosologie de la fibrillation auriculaire. Essai de clarifications. Arch Mal Coeur 1995; 88: 1035-8.
18. [18] Clémenty J, Safar M, Vrancea F. Cardiac arrhythmias in hypertension. Prospective study including 251 patients (Abstr). Eur Heart J 1989; 10: 201.
19. [19] Nunez BD, Messerli FH, Garavoglia GE, Schmieder RE. Exaggerated atrial and ventricular excitability in hypertensive patients with isolated septal hypertrophy (Abstr). J Am Coll Cardiol 1987; 9: 225 A.
20. [20] Robinson K, Frenneaux MP, Stockins B et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15: 1279-85.
21. [21] Haissaguerre M, Bonnet J, Billes MA et al. Prévalence, signification et pronostic des arythmies auriculaires dans les myocardiopathies dilatées. À propos de 236 cas. Arch Mal Coeur 1985; 4: 536-41.
22. [22] Evans W, Swann P. Lone auricular fibrillation. Br Heart J 1954; 16: 189-94.
23. [23] Waldo AL, MacLean WAH, Karp RB et al. Continuous rapid atrial pacing to control recurrent or sustained surpraventricular tachycardias following open heart surgery. Circulation 1976; 54: 254-50.
24. [24] Brugada R, Tapscott T, Czernuszewicz G et al. Identification of the first locus for familial atrial fibrillation utilizing a rapid novel pooled DNA strategy. (Abstr) Am Coll Cardiol 29 (Suppl II): 2A, 407-1.
25. [25] Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959; 58: 59-70.
26. [26] Rensma PL, Allessie MA, Lammers WJ et al. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410.
27. [27] Jais P, Haissaguerre M, Shah DC et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-6.
28. [28] Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-21.
29. [29] Allessie MA, Konings K, Kirchhof C. Mapping of atrial fibrillation. In: Olsson SB, Allessie MA, Campbell RWF, eds. Atrial Fibrillation: mechanisms and therapeutic strategies. Armonk NY: Futura Publishing Company 1994: 37-49.
30. [30] Gray RA, Pertsov AM, Jalife J. Incomplete reentry and epicardial breakthrough patterns during atrial fibrillation in the sheep heart. Circulation 1996; 94: 2649-61.
31. [31] Ricard Ph, Lévy S, Trigano J et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol 1997; 79: 815-6.
32. [32] Wijfells MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92: 1954-68.
33. [33] Attuel P, Pellerin D, Gaston J et al. Latent atrial vulnerability: new means of electrophysiologic investigations in paroxysmal atrial arrhythmias. In: Attuel P, Coumel P, Janse MJ, eds. The Atrium in Health and Disease. Mount Kisco, NY: Futura Publishing Company 1989: 159-200.
34. [34] Le Heuzey JY, Boutjdir M, Gagey S, Lavergne T, Guize L. Cellular aspect of atrial vulnerability. In: Attuel P, Coumel P, Janse MJ, eds. The Atrium in Health and Disease. Mount Kisco, New York: Futura Publishing Company, 1989: 81-94.
35. [35] Capucci A, Biffi M, Boriani G et al. Dynamic electrophysiologic behavior of human atria during paroxysmal atrial fibrillation. Circulation 1995; 92: 1193-202.
36. [36] Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-25.
37. [37] Olsson SB, Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand 1971; 190: 381-7.
38. [38] Michelucci A, Padeletti L, Porciani MC et al. Dispersion of refractoriness in atrial fibrillation. In: Olsson SB, Allessie MA, Campbell RWF eds. Atrial Fibrillation: Mechanisms and therapeutic strategies. Armonk NY: Futura Publishing Company, 1994: 81-107.
39. [39] Ramdat Missier AR, Opthof T, Van Hemel NM et al. Increased dispersion of refractoriness in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19: 1531-5.
40. [40] Cosio FG, Palacias J, Vidal JM, Cocina EG, Gomez-Sanchez MA, Tamargo L. Electrophysiological studies in atrial fibrillation. Slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol 1983; 51: 122-30.
41. [41] Edwards BS, Zimmerman RS, Schwab TR et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988; 62: 191-5.
42. [42] Spach MS. Non uniform anisotropic cellular coupling as a basis for reentrant arrhythmias. In: Di Marco JP, Prystowsky JP, eds. Atrial Arrhythmias. State of the art. Armonk, NY: Futura Publishing Company, 1995: 123-47.
43. [43] Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart; super sensitivity that may be arrhythmogenic. Circulation 1987; 75: 877-87.
44. [44] Cox JL, Canaven TE, Schuessler RB et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 406-26.
45. [45] Bharati S, Lev M. Histology of the normal and diseased atrium. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanism and Management. New York: Raven Press, 1992: 15-39.
46. [46] Guiraudon CM, Ernst NM, Guiraudon GM, Yee R, Klein GJ. The pathology of drug resistant lone atrial fibrillation in eleven surgically treated patients In: Kingma JH, Van Hemel NM, Lie KI, eds. Atrial fibrillation a Treatable disease? Dordrecht: Kluwer Academic Publishers, 1992: 41-57.
47. [47] Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 9: 1180-4.
48. [48] Coumel PH, Attuel P, Leclercq JF, Friocourt P. Arythmic auriculaire d'origine vagale ou catécholergique: effets comparés due traitement béta-bloquant et phénomène d'échappement. Arch Mal Coeur 1982; 75: 373-88.
49. [49] Lombardi F, Tozillo D, Cappiello E. Sympatho-vagal influence in atrial fibrillation. N Trends Arrhythmias 1993; 9: 279-84.
50. [50] Antiarrhythmic Therapy: A Pathophysiologic Approach by Members of the Sicilian Gambit. Armonk NY: Futura Publishing Company, 1994: 188-93.
51. [51] Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardson Th. Chronic atrial fibrillation-Epidemiologic features and 14 years follow-up: A case control study. Eur Heart J 1987; 3: 521-7.
52. [52] Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet 1987; 1: 526-9.
53. [53] Sherman OG, Hart RG, Easton JD. The secondary prevention of stroke in patients with atrial fibrillation. Arch Neurol 1986; 43: 68-70.
54. [54] Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986; 17: 622-6.
55. [55] Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-79.
56. [56] Van Latum JC, Koudstaal PJ, Venables GS et al. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke 1995; 25: 801-6.
57. [57] Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transoesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-9.
58. [58] Mügge A, Kühn H, Nikutta P et al. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: Identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23: 599-607.
59. [59] Shively BK, Gelgand EA, Crawford MH. Regional left atrial stasis during atrial fibrillation and flutter: Determinants and relation to stroke. J Am Coll Cardiol 1996; 27: 1722-7.
60. [60] Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
61. [61] The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-theumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
62. [62] Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in atrial fibrillation study; Final results. Circulation 1991; 84: 527-39.
63. [63] Connolly SJ, Laupacis A, Gent M et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Cardiol 1991; 18: 349-55.
64. [64] Singer DE. The randomized trials of warfarin for atrial fibrillation. N Engl J Med 1992; 327: 1451-3.
65. [65] Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
66. [66] European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
67. [67] The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Eng J Med 1995; 333: 5-10.
68. [68] Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-91.
69. [69] Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized double-blinded trial. Ann Inter Med 1987; 106: 503-6.
70. [70] Jordaens L, Trouerbach J, Calle P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 1997; 18: 643-8.
71. [71] The Digitalis in Acute Atrial Fibrillation (DAAF) trial group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997; 18: 649-54.
72. [72] Laupacis A, Alberts G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102 (Suppl): 426-31.
73. [73] Capucci A, Tiziano L, Boriani G et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70: 69-72.
74. [74] Crijns HJGM, van Vijk M, van Gilst WH, Herre Kingma J, van Gelder IC, Lie KI. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988; 9: 634-9.
75. [75] Suttorp MJ, Kingma HJ, Jessurun ER, Lie-A-Huen L, Van Hemel NM, Lie KI. The value of class 1C antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-7.
76. [76] Nacarelli GV, Dorian P, Hohnloser SH et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 75: 53A-59A.
77. [77] Lacombe P, Cointe R, Metge M, Bru P, Gérard R, Lévy S. Intravenous flecainide in the management of acute supra-ventricular tachyarrhythmias. J Electrophysiol 1988; 2: 19-21.
78. [78] Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994; 43: 305-11.
79. [79] Boriani G, Biffi M, Capucci A et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized controlled trial. Ann Intern Med 1997; 126: 621-4.
80. [80] Capucci A, Boriani G, Botto GL et al. Conversion of recent onset atrial fibrillation to sinus rhythm by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994; 74: 503-5.
81. [81] Aliot E, Denjoy I and the Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital-outpatients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 77 60A-65A.
82. [82] Feld GH, Chen PS, Nicod P, Fleck RP, Mezer D. Atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol 1990; 66: 378-82.
83. [83] Keller K, Meyer-Estorf G, Beck OA, Hochrein H. Correlation between serum concentration and pharmacological effect on atrioventricular conduction time of the antiarrhythmic drug propafenone. Eur J Clin Pharmacol 1978; 13: 1303-6.
84. [84] Tieleman RG, Gosselink ATM, Crijns HJGM et al. Efficacy, safety and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79: 53-7.
85. [85] Donovan KD, Dower BM, Hockings BE et al. Flecainide versus amiodarone for recent onset atrial fibrillation. Am J Cardiol 1995; 75: 693-7.
86. [86] Galve E, Rius T, Ballester R et al. intravenous amiodarone in the treatment of recent-onset atrial fibrillation. Results of a randomized, controlled trial. J Am Coll Cardiol 1996; 27: 1079-82.
87. [87] Ellenbogen KA, Wood M, Stambler BS et al. Conversion of atrial fibrillation and flutter by intravenous ibutilide; a multicenter dose response study. J Am Coll Cardiol 1996; 28: 130-6.
88. [88] Falk RH, Pollak A, Singh SN, Tilman F. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997; 29: 385-90.
89. [89] Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1962; 29: 469-89.
90. [90] Eway GA. Effectiveness of direct current of defibrillation. Role of paddle electrode size. Am Heart J 1977; 93: 674-5.
91. [91] Connell PN, Ewy GA, Dahl CF et al. Transthoracic impedance to defibrillator discharge; effect of electrode size and chest wall interface. J Electrophysiol 1973; 6: 313-7.
92. [92] Bjerkelund C, Orning OM. An evaluation of DC shock treatment of atrial arrhythmias; immediate results and complications in 437 patients with long term results in the first 290 of these. Acta Med Scand 1968; 184: 481-91.
93. [93] Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6.
94. [94] Van Gelder IC, Crijns HJGM, Hillege H, Lie KI. Value and limitations of DC electrical cardioversion of chronic atrial fibrillation. Pacing Clin Electrophysiol 1995; 18(II): 798.
95. [95] Lévy S , Lauribe P, Dolla E et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992; 86: 1415-20.
96. [96] Lévy S, Lacombe P, Cointe R et al. High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol 1988; 12: 514-8.
97. [97] Cooper RAS, Alferness CA, Smith WN, Ideker RE. Internal cardioversion of atrial fibrillation in sheep. Circulation 1993; 87: 1673-86.
98. [98] Alt E, Schmitt C, Ammer R et al. Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. Pace Pacing Clin Electrophysiol 1994; 17: 1067-78.
99. [99] Murgatroyd F, Slade AKB, Sopher M, Rowland E, Ward DE, Camm J. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995; 25: 1347-53.
100. [100] Lévy S, Ricard Ph, Pak Lau C et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial. Results in different subjects of atrial fibrillation. J Am Coll Cardiol 1997; 29: 750-5.
101. [101] Lévy S, Ricard Ph, Gueunoun M et al. Low-energy cardioversion of spontaneous atrial fibrillation. Circulation 1997; 96: 253-9.
102. [102] Schmitt C, Alt E, Plevan A et al. Low-energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996; 28: 994-9.
103. [103] Barold H, Warton JM. Ventricular fibrillation resulting from synchronized internal defibrillation in a patient with ventricular preexcitation. J Cardiov Electrophysiol 1997; 8: 436-40.
104. [104] Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23: 208-16.
105. [105] Manning WJ, Silverman DI, Gordon SP et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-5.
106. [106] Black IW, Fatkin D, Sagar KB. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study. Circulation 1994; 89: 2509-13.
107. [107] Grimm RA, Stewart WJ, Maloney JD et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359-66.
108. [108] Prystowsky EN, Benson Jr W, Fuster V et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology of the American Heart Association. Circulation 1996; 93: 1262-77.
109. [109] Klein AL, Grimm RA et al. Cardioversion guided by transesophageal echocardiography; the ACUTE Pilot Study: a randomized, controlled trial. Ann Intern Med 1997; 126: 200-9.
110. [110] Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
111. [111] Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64: 1317-21.
112. [112] Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-41.
113. [113] Zehender M, Hohnloser S, Lüller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19: 1054-9.
114. [114] Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-93.
115. [115] Juül-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-9.
116. [116] Antman EM, Beamer AD, Cantillon C et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698-707.
117. [117] The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial Fibrillation follow-up investigation of rhythm management - The AFFIRM Study design. Am J Cardiol 1997; 79: 1198-202.
118. [118] Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology. From cell to bedside. Philadelphia, PA: WB Saunders, 1990: 330-43.
119. [119] Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation 1989; 80: 1557-70.
120. [120] Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter; Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 1991; 67: 713-7.
121. [121] Clémenty J, Dulhoste M, Laiter C, Denjoy I, Dos Santos P. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70: 44A-49A.
122. [122] Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114: 539-44.
123. [123] Cobbe SM, Rae AP, Polioniecki JD et al. UK Propafenone PSVT Group. A randomized placebo-controlled trial in the prevention of paroxysmal supraventricular tachycardia and atrial fibrillation. Circulation 1995; 92: 2550-7.
124. [124] Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-63.
125. [125] Jackman WM, Friday KJ, Andersen JL, Aliot EM, Clark M, Lazarra R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-72.
126. [126] Hohnloser SH, Van Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995; 26: 852-8.
127. [127] Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107-11.
128. [128] Sihm I, Hansen FA, Rasmussen J, Pedersen AK, Thygesen K. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. Eur Heart J 1990; 11: 145-8.
129. [129] Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991; 67: 976-80.
130. [130] Daoud EG, Weiss R, Bahu M et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78: 1433-6.
131. [131] Langendorf R, Pick A, Katz LN. Ventricular response in atrial fibrillation: role of concealed conduction in the AV junction. Circulation 1965; 32: 69-72.
132. [132] Toivonen L, Kadish A, Kou W et al. Determinants of the ventricular rate during atrial fibrillation. J Am Coll Cardiol 1990; 16: 1194-200.
133. [133] Chorro FJ, Kirchlof CJHJ, Brugada J, Allessie MA. Ventricular response during irregular atrial pacing and atrial fibrillation. Am J Physiol 1990; 259: H1015.
134. [134] Rawles JM. What is meant by a 'controlled' ventricular rate in atrial fibrillation? Br Heart J 1990; 63: 157-61.
135. [135] Resnekov L, McDonald L. Electroversion of lone atrial fibrillation and flutter including hemodynamic studies at rest and on exercise. Br Heart J 1971; 33: 339-50.
136. [136] Atwood JE, Myers J, Sandhu et al. Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation. Am J Cardiol 1989; 63: 45-8.
137. [137] Frey B, Heinz G, Binder T et al. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. Am Heart J 1995; 129: 58-65.
138. [138] Stein KM, Borer JS, Hochreiter C, Devereux RB, Kligfield P. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. Am J Cardiol 1994; 74: 906-11.
139. [139] Coumel P, Thomas O, Leenhardt A. Drug therapy for prevention of atrial fibrillation. Am J Cardiol 1996; 77 (Suppl): 3A-9A.
140. [140] Lemery R, Brugada P, Cheriex E, Wellens HJJ. Reversibility of tachycardia-induced dysfunction after closed chest ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol 1987; 60: 1406-8.
141. [141] Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1570-3.
142. [142] David G, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta-adrenergic blocking agent. Am J Cardiol 1979; 44: 1378-82.
143. [143] Rawles M, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63: 225-7.
144. [144] Roberts SA, Diaz C, Nolan PE et al. Effectiveness and cost of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72: 567-73.
145. [145] Murgatroyd FD, O'Nunian S, Gibson SM et al. The results of CRAFT-1: a multi-center, double-blind, placebo-controlled crossover study of digoxin in symptomatic paroxysmal atrial fibrillation (Abstr). J Am Coll Cardiol 1993; 21: 478 A.
146. [146] Ellenbogen KA, Dias VC, Plumb VJ et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter. A multicenter study. J Am Coll Cardiol 1991; 18: 891-7.
147. [147] Rikkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil. Circulation 1980; 62: 996-1010.
148. [148] Daoud EG, Knight BP, Weiss R et al. Effect of verapamil and procainamide on atrial fibrillation. Induced electrical remodeling in humans. Circulation 1997; 96: 1542-50.
149. [149] Platia EV, Michelson EL, Porterfield JK et al. Esmololol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. A multicenter study. Am J Cardiol 1989; 63: 925-9.
150. [150] Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989; 13: 1-6.
151. [151] James MA, Channer KS, Papouchado M, Rees JR. Improved control of atrial fibrillation with combined pindolol and digoxin therapy. Eur Heart J 1989; 10: 83-90.
152. [152] Atwood JE, Sullivan M, Forbes S et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987; 10: 14-20.
153. [153] Scardi S, Humar F, Pandullo C, Poletti A. Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet 1993; 341: 1211-2.
154. [154] McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Int Med 1986; 104: 791-4.
155. [155] Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J 1983; 106: 145-7.
156. [156] Markevitz A, Schad N, Hemmer W, Berheim C, Ciavolollela M, Weinhold C. What is the most appropriate stimulation mode in patients with node dysfunction? Pacing Clin Electrophysiol 1986; 9: 1115-20.
157. [157] Zanini R, Facchinetti A, Gallo G et al. Morbidity and mortality in patients with sinus node disease: comparative effects of atrial and ventricular pacing. Pacing Clin Electrophysiol 1990; 13: 2076-9.
158. [158] Rosenqvist M, Brandt J, Schuller H. Long-term pacing in sinus node disease: the effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J 1988; 116: 16-22.
159. [159] Hesselson AB, Parsonnet V, Bernstein AD et al. Deleterious effects of long-term single-chamber ventricular pacing in patients with sick sinus syndrome: the hidden benefits of dual-chamber pacing. J Am Coll Cardiol 1992; 19: 1542-9.
160. [160] Santini M, Alexidou G, Ansalone G, Cacciatore G, Cina R, Turitto G. Relation of prognosis in sick sinus syndrome to age, conduction defects and modes of permanent cardiac pacing. Am J Cardiol 1990; 65: 729-35.
161. [161] Andersen HR, Theusen L, Bagger J et al. Prospective randomized trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994; 344: 1923-8.
162. [162] Dreyfus LS, Fisch C, Griffin JC et al. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the ACC/AMA task force on assessment of diagnostic and therapeutic cardiovascular procedures. J Am Coll Cardiol 1991; 18: 1-13.
163. [163] Scheinman MM, Morady F, Hess DS et al. Catheter-induced ablation of the atrioventricular junction to control refractory supra ventricular arrhythmias. JAMA 1982; 248: 851-5.
164. [164] Gallagher JJ, Svenson RH, Kasell JH et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system: a therapeutic alternative for the treatment of refractory supraventricular tachycardia. N Engl J Med 1982; 306: 194-200.
165. [165] Guarrigue S, Cazeau S, Ritter P, Lazzarus A, Mugica J. Diagnostic des arythmies supraventriculaires au long cours en stimulation double chambre. Apport du monitoring permanent par la fonction holter implantée du stimulateur. Arch Mal Coeur 1996; 89: 873-9.
166. [166] Daubert C, Mabo P, Berder V, Gras D, Leclerq C. Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronization. Eur J Cardiac Pacing Electrophysiol 1994; 4: 35-44.
167. [167] Saksena S, Prakash A, Hill M et al. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28: 687-94.
168. [168] Lévy S, Camm AJ. An implantable atrial defibrillator: an impossible dream? Circulation 1993; 87: 1769-72.
169. [169] Saksena S, Prakash A, Mangeon L et al. Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations. Am J Cardiol 1995; 76: 913-21.
170. [170] Ayers GM, Alferness CA, Ilina M et al. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation 1994; 89: 413-22.
171. [171] Timmermans C, Lau CP, Tse HF, Jordaens LJ, Wellens HJJ. Early experience with the metrix implantable defibrillator (Abstr). Eur Heart J 1997; 18 (Abstr Suppl 892): 134.
172. [172] Jung W, Lüderitz B. Implantation of an arrhythmia management system for ventricular and supraventricular tachyarrhythmias. Lancet 1997; 349: 853-5.
173. [173] Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991; 101: 584-92.
174. [174] Cox JL, Schuessler RB, Lappas DG et al. An 81/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 1996; 224: 267-75.
175. [175] Kawaguchi AT, Kosakai Y, Sakso Y et al. Risks and benefits of combined maze procedure for atrial fibrillation associated with organic heart disease. J Am Coll Cardiol 1996; 28: 985-90.
176. [176] Graffigna A, Pagani F, Minzioni G, Salerno J, Vigano M. Left atrial isolation associated with mitral valve operations. Ann Thorac Surg 1992; 54: 1093-8.
177. [177] Kosakai Y, Kawaguchi AT, Isobe F et al. Modified maze procedure for patients with atrial fibrillation undergoing simultaneous open heart surgery. Circulation 1995; 92,II: 359-64.
178. [178] McCarthy P, Cosgrove D, Castle LW, White RD, Klein AL. Combined treatment of mitral regurgitation and atrial fibrillation with valvuloplasty and the Maze Procedure. Am J Cardiol 1993; 71: 483-6.
179. [179] McComb JM. Surgery for atrial fibrillation. Br Heart J 1994; 71: 501-3.
180. [180] Tsui SSL, Grace AA, Ludman PF et al. Maze 3 for atrial fibrillation: two cuts too few? PACE 1994; 17: 2163-6.
181. [181] Feinberg M, Waggoner AD, Kater K et al. Assessment of left atrial function after the Maze Procedure by Doppler echocardiography (Abstr). Circulation 1993; 88 (Suppl I): 482.
182. [182] Tamai J, Kosakai Y, Yoshioka T, Ohnishi E et al. Delayed improvement in exercise capacity with restoration of sinoatrial node response in patients after combined treatment with surgical repair of organic heart disease and the maze procedure for atrial fibrillation. Circulation 1995; 91: 2392-9.
183. [183] Crijns HJ, Van Gelder IC, Van der Woude HJ et al. Efficacy of serial electrical cardioversion therapy in patients with chronic atrial fibrillation after valve replacement and implications for surgery to cure atrial fibrillation. Am J Cardiol 1996; 78: 1140-4.
184. [184] Leich JW, Klein G, Yee R, Guiraudon G. Sinus node atrioventricular isolation: long term results with the 'Corridor' operation for atrial fibrillation. J Am Coll Cardiol 1991; 17: 970-5.
185. [185] Poquet F, Clémenty J, Gencyl L. et al. Survie après fulguration du faisceau de His pour arythmie supraventriculaire. Arch Mal Coeur 1995; 88: 1593-600.
186. [186] Rosenqvist M, Lee M, Moulinier L. et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol 1990; 16: 1467-74.
187. [187] Evans T, Scheinman M, Zipes D et al. The percutaneous cardiac mapping and ablation registry: final summary of results. Pacing Clin Electrophysiol 1988; 11: 1621-6.
188. [188] Lévy S, Bru P, Aliot E et al. Long-term follow-up of atrioventricular junctional transcatheter electrical ablation. Pacing Clin Electrophysiol 1988; 11: 1149-53.
189. [189] Evans T. Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction. Results of a prospective, international, multicenter study. Circulation 1991; 84: 1924-37.
190. [190] Huang SKS. Advances in applications of radiofrequency current to catheter ablation therapy. Pace Pacing Clin Electrophysiol 1991; 14: 28-42.
191. [191] Jackman WM, Wang X, Friday KJ et al. Catheter ablation of atrioventricular junction using radiofrequency current in 17 patients. Comparison of standard and large-trip catheter electrodes. Circulation 1991; 83: 1562-76.
192. [192] Morady F, Calkins H, Langberg JJ et al. A prospective randomized comparison of direct current and radio frequency ablation of the atrio-ventricular junction. J Am Coll Cardiol 1993; 21: 102-9.
193. [193] Yeung-Lai-Wah JA, Alison JF, Lonergan L et al. High success rate of atrioventricular node ablation with radiofrequency energy. J Am Coll Cardiol 1991; 18: 1753-8.
194. [194] Olgin JE, Scheinman MM. Comparison of direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 1993; 21: 557-64.
195. [195] Trohman R, Simmons T, Moore S et al. Catheter ablation of the atrioventricular junction using radiofrequency energy and a bilateral cardiofrequency catheter ablation of arrhythmias. Eur Heart J 1993; 14: 1644-53.
196. [196] Twidale N, Sutton K, Bartlett L et al. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. Pace Pacing Clin Electrophysiol 1993; 16: 1275-84.
197. [197] Kay N, Bubien R, Epstein A et al. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988; 62: 741-4.
198. [198] Rodriguez LM, Smeets J, Xie B et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993; 72: 1137-41.
199. [199] Brignole M, Gianfranchi L, Menozzi C et al. Assessment of atrioventricular junction ablation and DDDR mode switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation. A randomized controlled study. Circulation 1997; 96: 2617-24.
200. [200] Hindricks G. The Multicenter European Radiofrequency Survey (MERFS): complications of radiofrequency ablation. Am J Cardiol 1992; 70: 1438-43.
201. [201] Williamson B, Ching Man K, Daoud E et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331: 910-7.
202. [202] Brignole M, Menozzi C, Gianfanchi L et al. Single-session step-wise radiofrequency catheter modification at atrioventricular conduction in patients with paroxysmal atrial fibrillation. Eur JCPE 1995; 5: 18-22.
203. [203] Feld G, Felck P, Fujimura O. et al. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular mode in patients with medically refractory atrial fibrillation. Circulation 1994; 90: 2299-307.
204. [204] Della Bella P, Carbucicchio C, Tondo C et al. Modulation of atrioventricular conduction by ablation of the 'slow' atrioventricular node pathway in patients with drug-refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995; 25: 39-46.
205. [205] Menozzi C, Brignole M, Gianfranci L et al. Radiofrequency catheter ablation and modulation of atrioventricular conduction in patients with atrial fibrillation. Pace Pacing Clin Electrophysiol 1994; 17: 2143-9.
206. [206] Duckeck W, Engelstein E, Juck KH. Radiofrequency current therapy in atrial tachyarrhythmias: modulation versus ablation of atrioventricular nodal conduction. Pacing and Clinical Electrophysiol 1993; 16: 629-36.
207. [207] Chen SA, Lee SH, Chiang CE et al. Electrophysiological mechanisms in successful radiofrequency modification of atrioventricular junction for patients with medically refractory paroxysmal atrial fibrillation. Circulation 1996; 93: 1690-701.
208. [208] Morady F, Hasse C, Strickberger A et al. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 1997; 27: 113-21.
209. [209] Haissaguerre M, Gencel L, Fischer B et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5: 1045-52.
210. [210] Haissaguerre M. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-44.
211. [211] Swartz JF, Pellersels G, Silvers J et al. A catheter-based curative approach to AF in humans (Abstr). Circulation 1994; 90 (Part 2) I: 335.
212. [212] Elvan A, Huan XD, Pressler ML, Zipes DP. Radiofrequency catheter ablation of the atria eliminates pace-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation 1997; 96: 1675-85.
213. [213] Konings KTS, Kirchhof CJHJ, Smeets JRLM, Wellens HJJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994; 89: 1665-80.